hepatitis B

Latest Headlines

Latest Headlines

Dynavax shares hammered on FDA clinical hold

Dynavax's shares took a beating this morning after the FDA placed a clinical hold on the company's trial of Heplisav, a hepatitis B therapy. According to the Motley Fool, "[t]he agency put the

Rare disease puts Phase III vax trial on hold

The FDA has placed a hold on a late-stage trial of an experimental hepatitis B vaccine after one of the patients in the test was diagnosed with a rare inflammatory condition. Researchers for Merck

ALSO NOTED: YM cuts losses;French launch vaccines probe; diabetes foundation contributes research funds; and much more...

> YM Biosciences managed to halve its pre-tax loss for the first half by cutting expenses.

Cangene consolidates, cuts staff

Canada's Cangene announced that it is consolidating all R&D activities within the Winnipeg head office location and cutting its staff by 4 percent. Cangene says its consolidating in order to

Idenix restructures, cuts workforce

Idenix Pharmaceuticals is shifting its R&D operations away from its hepatitis B treatment Tyzeka to focus on the development of hepatitis C virus and HIV programs. Idenix has

Roche halts Phase I trial

Roche has halted a trial of MAXY-alpha, also known as R7025, due to an unanticipated reduction of the pharmacodynamic and pharmacokinetic effects in patients who received the drug. Roche and

Nabi sells unit for $185M, plans Maryland move

Nabi Biopharmaceuticals plans to sell its biologics unit to Germany's Biotest for $185 million. Biotest gains a headquarters facility in Boca Raton, a plasma protein plant, Nabi-HB Hepatitis B immune

Anadys dumps hep B compound in restructuring

Anadys Pharmaceuticals in San Diego is also restructuring to account for a development failure. Out the door go 29 of 88 employees as it halts work on ANA975 for hepatitis B. Toxicology testing on

Metabasis stock tanks on double dose of bad news

Metabasis Therapeutics announced a pair of setbacks on Tuesday, saying that Schering-Plough is pulling out of a collaboration to develop a new therapy for hepatitis B and that an experimental

Idenix sees little hope for hep C candidate

Cambridge, MA-based Idenix is preparing a formal burial for valopicitabine, an experimental therapy for hepatitis C. CEO Jean-Pierre Sommadossi says he believes that the FDA's decision that the